{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:21:48Z","timestamp":1766514108228},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1097\/md.0000000000001364","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T20:05:55Z","timestamp":1440619555000},"page":"e1364","source":"Crossref","is-referenced-by-count":7,"title":["A Case Report on Dyskinesia Following Rivastigmine Patch 13.3\u200amg\/24\u200ahours for Alzheimer's Disease"],"prefix":"10.1097","volume":"94","author":[{"given":"Maria Cristina B.","family":"Diaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond L.","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210309","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000255578","article-title":"Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimers disease: systematic review of the real world evidence.","volume":"28","author":"Lockhart","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R2-11-20210309","first-page":"194","article-title":"Cholinesterase inhibitors in the real world setting: rivastigmine versus donepezil tolerability and effectiveness study.","volume":"2","author":"Sobow","year":"2006","journal-title":"Arch Med Sci"},{"key":"R3-11-20210309","first-page":"421","article-title":"Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimers disease over a six-month period.","volume":"36","author":"Turon-Estrada","year":"2003","journal-title":"Rev Neurol"},{"key":"R4-11-20210309","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneurol.2009.96","article-title":"Frequency characteristics, and risk factors for amiodarone neurotoxicity.","volume":"66","author":"Orr","year":"2009","journal-title":"Arch Neurol"},{"key":"R5-11-20210309","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.parkreldis.2009.02.015","article-title":"The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.","volume":"15","author":"Go","year":"2009","journal-title":"Park Rel Dis"},{"key":"R6-11-20210309","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/jnnp.37.8.941","article-title":"Effect of cholinergic and anticholinergic agents on tardive dyskinesia.","volume":"37","author":"Klawans","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R7-11-20210309","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics and the risk of death in patients with dementia number needed to harm.","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"R8-11-20210309","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s10072-012-1242-3","article-title":"Donepezil induced antecollis in a patient with Parkinsons disease dementia.","volume":"34","author":"Oh","year":"2013","journal-title":"Neurol Sci"},{"key":"R9-11-20210309","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1440-1819.2011.02196.x","article-title":"Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with dementia with Lewy bodies.","volume":"65","author":"Shinfuku","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"key":"R10-11-20210309","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1177\/1060028014550334","article-title":"Donepezil-induced myoclonus in a patient with Alzheimer disease.","volume":"48","author":"Bougea","year":"2014","journal-title":"Ann Pharmacother"},{"key":"R11-11-20210309","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.20164","article-title":"Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.","volume":"19","author":"Cossu","year":"2004","journal-title":"Mov Dis"},{"key":"R13-11-20210309","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.2146\/ajhp060399","article-title":"Rivastigmine-induced dystonia.","volume":"64","author":"Pavlis","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"R14-11-20210309","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1017\/S104161021300029X","article-title":"Acute dystonic reaction with rivastigmine.","volume":"25","author":"Dhikav","year":"2013","journal-title":"Int Psychogeriatr"},{"key":"R15-11-20210309","first-page":"86","article-title":"From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.","volume":"29","author":"Rene","year":"2014","journal-title":"Neurologia"},{"key":"R16-11-20210309","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0161-813X(01)00044-4","article-title":"Acetylcholinesterase inhibition and the extrapyramidal syndrome: a review of the neurotoxicity of organophosphate.","volume":"22","author":"Hsieh","year":"2001","journal-title":"Neurotoxicology"},{"key":"R17-11-20210309","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/jnnp.66.2.253","article-title":"Transient severe parkinsonism after acute organophosphate poisoning.","volume":"66","author":"Muller-Vahl","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:48:31Z","timestamp":1620960511000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201508040-00011"}},"subtitle":["Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors"],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":16,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001364","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}